According to the latest
market report published by Credence Research, Inc. “Cervical
Dysplasia Diagnostic Market By Type (Diagnostic Test, Diagnostic
Device) - Growth, Future Prospects, and Competitive Analysis, 2017 -
2025,” the global cervical dysplasia diagnostic market was valued at US$
437.3 million in 2016 and is anticipated to reach US$ 791.3 million by 2025,
increasing CAGR by 6.5 percent from 2017 to 2025
Market Insights
Cervical dysplasia,
also known as cervical intraepithelial neoplasia (CIN), triggers abnormal cell
growth that happens on the epithelial lining of the cervix. It is the
precancerous condition of the cervix that is expected to advance to cervical
cancer in an average of 10-15 years. There is a prevalent health problem among
females. WHO and domestic governments are taking measures to provide a
screening program and efficient education to encourage preventive practices
among females. About 250,000 to 1 million females in the U.S. are diagnosed
with cervical dysplasia every year.
Browse the
full report at https://www.credenceresearch.com/report/cervical-dysplasia-diagnostic-market
The maximum incidence
in females varies from 25-35 years of age and, if not diagnosed or treated at
the earliest, in 30-40 percent of instances, invasive cancer may develop.
Cervical cancer is a worldwide burden, particularly in developing nations where
it is the most prevalent cause of preventable cancer-related mortality. As a
result, the increasing incidence of cervical dysplasia and the development of
diagnostic technology and therapy options are important factors contributing to
the development of the cervical dysplasia diagnostic industry.
The worldwide market
for diagnostic cervical dysplasia is segmented into diagnostic test and
diagnostic devices by type of diagnosis. Diagnostic test kinds are further
segmented into HPV, Pap and Biopsy tests.
As in the present
business situation, North America dominates the worldwide market for diagnostic
cervical dysplasia followed by Europe. Rising incidence of cervical dysplasia,
progress in diagnostic technology, awareness of cervical cancer and accessible
novel therapy options are some of the key variables driving the development of
the cervical dysplasia diagnostic industry in North America and Europe. Asia
Pacific is the fastest-growing regional market for cervical dysplasia with the
largest CAGR in the forecast period.
Download
Free PDF Sample Request: https://www.credenceresearch.com/sample-request/58678
Market Competition
Assessment:
Key players in the
global cervical dysplasia diagnostic market are Abbott Laboratories, Becton,
Dickinson and Company, F. Hoffmann La-Roche Ltd., GlaxoSmithKline Plc, Helix
BioPharma Corp., Hologic, Inc., Inovio Biomedical Corporation, Micromedic
Technologies Ltd., OncoHealth Corporation, PDS Biotechnology Corporation,
Photocure ASA, Quest Diagnostics, Inc., QIAGEN N.V. and others.
Key Market Movements:
- Increase in incidence and mortality
of cervical cancer is leading to global burden especially in developing
countries. In developed countries government is taking initiatives for
screening programs with goal of early diagnosis and treatment of cervical
dysplasia which play pivotal role in growth of cervical dysplasia
diagnostic market.
- Advancement in diagnostic
technology and novel drug treatment option available in market would
further propel the growth of cervical dysplasia diagnostic market.
Report Scope by
Segments
By Type of Diagnosis
- Diagnostic Test
- HPV Test
- Pap Smear Test
- Biopsy
- Diagnostic Device
- Colposcopy
By Geography Segment
- North America
- Europe
- Asia Pacific (APAC)
- Middle East & Africa (MEA)
- Latin America
No comments:
Post a Comment